The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI, in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). We hypothesized that we would observe a reduction in inflammatory-driven phenotypes of coronary plaque, including non-calcified coronary plaque burden and lipid-rich necrotic core in those treated with biologic therapy after one-year compared with non-biologic therapy.

and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Ortho Dermatologics. 3.Dr. Tawakol reports grants from Genentech and Actelion for research outside the submitted work. 4.Dr. Powell-Wiley has received funding from the National Institutes of Health Intramural Research Program (ZIA HL006168).

No abstract